Pharmaceutical Technology on MSN
FDA approves UCB’s Kygevvi for genetic mitochondrial disease
The approval was based on data from a Phase II trial, two retrospective chart review studies and an expanded access programme ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback